Introduction

Proneuron Biotechnologies, a Delaware company, is in advanced stages of clinical development in a number of attractive neurological markets. Proneuron is the first company to harness the power of the body's own immune system for the treatment of debilitating central nervous system (CNS) disorders. The Company was founded in 1996 based upon the groundbreaking research of Professor Michal Schwartz of the Weizmann Institute of Science, who demonstrated the role of immune response in normal and pathological conditions in the CNS. Proneuron is determined to establish itself as a fully integrated company that will independently develop and commercialize therapies for niche CNS disorders.

Proneuron is currently focusing its expertise in cell therapy and neuroimmunology on the development and commercialization of treatments for spinal cord injuries (SCI) as well as other neurological disorders, which until now were considered incurable.

Proneuron's double layer business approach - a fully integrated niche CNS company and a source for product licensing for large pharma and biotech players, creates a wealth of potential revenue sources with a balanced risk profile.